5-氟-2-硝基苄醇 | 287121-32-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氟-2-硝基苄醇
• 中文别名: (5-氟-2-硝基苯基)甲醇；2-硝基-5-氟苯甲醇
• 英文名称: (5-Fluoro-2-nitrophenyl)-methanol
• 英文别名: (5-fluoro-2-nitrophenyl)methanol；5-fluoro-2-nitrobenzyl alcohol；2-hydroxymethyl-4-fluoronitrobenzene；(5-fluoro-2-nitro-phenyl)-methanol；(5-Fluoro-2-nitrophenyl) methanol
• CAS: 287121-32-8
• 化学式: C₇H₆FNO₃
• mdl: MFCD06202666
• 分子量: 171.128
• InChiKey: CWOZQRGVHQIIJL-UHFFFAOYSA-N

物化性质

• 沸点：
  286.1±25.0 °C(Predicted)
• 密度：
  1.434±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P264,P270,P301+P312,P330
• 危险性描述：
  H302,H315,H320,H335
• 储存条件：
  保存在2至8°C的环境中，需要密封并保持干燥。

反应信息

• 作为反应物：
  描述：

  5-氟-2-硝基苄醇 在 重铬酸吡啶 、 4 A molecular sieve 、 对甲苯磺酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 9.0h， 生成 2-(二丁氧基甲基)-4-氟-1-硝基苯
  参考文献：
  名称：

  Substituted 3-Imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino- [6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as Highly Selective and Potent Inhibitors of Glycogen Synthase Kinase-3

  摘要：

  Glycogen synthase kinase-3 (GSK3) is involved in signaling from the insulin receptor. Inhibitors of GSK3 are expected to effect lowering of plasma glucose similar to insulin, making GSK3 an attractive target for the treatment of type 2 diabetes. Herein we report the discovery of a series of potent and selective GSK3 inhibitors. Compounds 7-12 show oral activity in an in vivo model of type II diabetes, and 9 and 12 have desirable PK properties.

  DOI：

  10.1021/jm049768a
• 作为产物：
  描述：

  5-氟-2-硝基苯甲酸 在 borane tetrahydrofuran 、 甲醇 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以to provide 0.48 g (100%) of a white solid的产率得到5-氟-2-硝基苄醇
  参考文献：
  名称：

  2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids

  摘要：

  具有以下化学式的化合物：对于介导基质金属蛋白酶和TACE的疾病条件，例如肿瘤生长、骨关节炎、类风湿性关节炎和退行性软骨丢失具有治疗作用。

  公开号：

  US06544984B1

文献信息

• ARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES
  申请人：Dolente Cosimo

  公开号：US20110245237A1

  公开（公告）日：2011-10-06

  The present invention is concerned with aryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I wherein R 1 , R 2 and R 3 are as described herein. The invention further provides methods for the manufacture of such compounds and pharmaceutical compositions containing them. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists. The compounds are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明涉及式I的芳基-环己基-四氮杂苯并[e]吲哚类化合物 其中R1，R2和R3如本文所述。本发明进一步提供了制造此类化合物的方法和包含它们的药物组合物。根据发明的化合物作为V1a受体调节剂，特别是作为V1a受体拮抗剂。这些化合物作为治疗剂在周围和中枢条件下对痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、血管加压素分泌不当、肝硬化、肾病综合征、焦虑、抑郁障碍、强迫症、孤独症谱系障碍、精神分裂症和攻击性行为是有用的。
• [EN] ARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES<br/>[FR] ARYL-CYCLOHEXYL-TÉTRAAZABENZO[E]AZULÈNES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011120877A1

  公开（公告）日：2011-10-06

  The present invention is concerned with aryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I, wherein R1, R2 and R3 are as described herein. The compounds according to the invention act as Via receptor modulators, and in particular as Via receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明涉及式I的芳基-环己基-四氮杂苯并[e]吲哚类化合物，其中R1，R2和R3如本文所述。根据发明的化合物作为Via受体调节剂，特别是作为Via受体拮抗剂，它们的制造，含有它们的药物组合物以及它们作为药物的使用。本发明的活性化合物作为治疗剂，在痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、不适当的血管升压素分泌、肝硬化、肾病综合征、焦虑、抑郁障碍、强迫症、孤独症谱系障碍、精神分裂症和攻击性行为的条件中，在周围和中心部位发挥作用。
• HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES
  申请人：Dolente Cosimo

  公开号：US20110263578A1

  公开（公告）日：2011-10-27

  The present invention is concerned with heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I wherein R 1 , R 2 and R 3 are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明涉及式I所示的杂芳基-环己基-四氮杂苯并[e]氮杂蒽衍生物， 其中R1、R2和R3如本文所述。 根据发明的化合物作为V1a受体的调节剂，尤其是作为V1a受体拮抗剂，它们的制造方法、含有它们的药物组合物以及它们作为药物的使用。本发明的活性化合物作为治疗剂，在周围和中枢条件下对痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、血管加压素的不当分泌、肝硬化、肾病综合征、焦虑、抑郁障碍、强迫症、孤独症谱系障碍、精神分裂症和侵略性行为有治疗作用。
• Enantioselective Organocatalytic Intramolecular Aza-Diels-Alder Reaction
  作者：Lucie Jarrige、Florent Blanchard、Géraldine Masson

  DOI：10.1002/anie.201705746

  日期：2017.8.21

  A highly efficient catalytic enantioselective intramolecular Povarov reaction was developed with primary anilines as 2‐azadiene precursors. A wide variety of angularly fused azacycles were obtained without column chromatography in high to excellent yields and with excellent diastereo‐ and enantioselectivity (d.r.>99:1 and up to e.r. 99:1). Furthermore, the catalyst loading could be lowered to 1 mol %

  开发了一种高效的催化对映选择性分子内Povarov反应，以伯苯胺作为2-氮杂二烯的前体。无需柱色谱，即可获得各种成角度的稠合氮杂环化合物，高产率至优异产率，非对映异构体和对映异构体选择性高（dr> 99：1，最高可达er er 99：1）。此外，催化剂负载量可以降低至1mol％，并且所获得的氮杂环化合物可以用作进一步转化以产生额外的分子多样性的关键中间体。
• [EN] PURINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES DE LA PURINE EN TANT QU'INHIBITEURS DE LA KINASE
  申请人：LILLY CO ELI

  公开号：WO2003076442A1

  公开（公告）日：2003-09-18

  The present invention provides kinase inhibitors of Formula I.

  本发明提供了化合物I的激酶抑制剂。